Six new lawsuits hit Novo Nordisk, and none say why yet

On Tuesday, September 15, 2026, six new lawsuits against Novo Nordisk landed on the docket, each tied to Ozempic, Wegovy, or GLP-1 drugs more broadly. None of them have released their actual claims yet. For anyone taking these medications or watching the litigation around them, that matters because the details, once unsealed, could shape what plaintiffs allege about side effects, marketing, or informed consent. Right now, all we know for certain is who is suing and who they're suing.

Helms v. Novo Nordisk, Inc. is the first of these new filings, and it names an individual plaintiff rather than a class, which typically means the person believes their situation involves facts specific to them. The court record does not yet describe what those facts are, whether they involve a diagnosis, a prescription history, or an alleged injury tied to Ozempic or Wegovy. This is normal at the early stage of litigation, since complaints are sometimes filed under seal or with limited public detail while attorneys finish assembling the full case. Readers who want to understand what Helms is actually alleging will need to wait for the complaint itself, or for a later court filing, to become public.

Hennessee v. Novo Nordisk A/S stands out because it names the parent company using its A/S designation, rather than only a U.S.-based Novo Nordisk entity that other plaintiffs have targeted. That choice can matter in product liability cases, since it may reflect where the plaintiff's attorneys believe key decisions, like drug design or safety testing, were made. As with Helms, the substance of Hennessee's claims about Ozempic and Wegovy has not been disclosed. If the case proceeds, the choice to sue the parent entity rather than a subsidiary could become a point of dispute over jurisdiction before the underlying allegations are even addressed.

Cinquemani v. Novo Nordisk Inc. follows the same pattern as the others on this list: a case is on the docket, but the claims inside it are not yet available to the public. This kind of gap between filing and disclosure can be common in the early days of a lawsuit, especially when a case is one of several being filed around the same time against the same company. It does not necessarily signal anything unusual about the case itself. For now, the only confirmed fact is that Cinquemani has taken legal action against Novo Nordisk over its GLP-1 products.

Rogers v. Novo Nordisk, Inc. lists both Ozempic and Wegovy in its case description, using 'or' rather than naming one drug specifically. That kind of language may show up when a docket entry is created before the full complaint becomes public, since general descriptions are sometimes used until more specific filings arrive. It does not tell us which drug, or whether both, form the basis of the Rogers claim. As with the other cases here, the actual allegations remain sealed from public view, and readers should treat the entry as a placeholder until more details surface.

Kably v. Novo Nordisk Inc. brings the count of new GLP-1 lawsuits against the company to six as of this tracking period, and like the rest, it offers no details about what the plaintiff is claiming. Taken together, these filings suggest a docket that is growing steadily, even though the public record has not caught up with the substance of any individual case yet. That gap between volume and detail is worth watching, since it means the current wave of litigation could involve a range of different allegations once the claims become visible. Kably's case adds to that uncertainty rather than resolving it.

For readers following GLP-1 litigation, the honest takeaway from these six filings is that there is not yet enough information to draw conclusions about what Novo Nordisk is being accused of in any of them. I would suggest checking back as court records update, since sealed or undisclosed claims often become public within weeks of filing. In the meantime, it makes sense to watch for two things: whether any of these cases get consolidated with existing GLP-1 litigation, and whether the underlying allegations, once unsealed, describe a common pattern of harm. Until then, the names Helms, Hennessee, Cinquemani, Rogers, and Kably mark filings to watch, not conclusions to act on.

By Amanda Bonello